secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lunai Bioworks Inc. (LNAI)
CIK:        0001527728
Form:       8-K
Filed at:   2025-01-07T23:59:59+00:00
Accession:  0001731122-25-000037
Event type: m_and_a
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Renovaro signs binding LOI to buy Predictive Oncology; preferred stock valued at $3/share
--------------------------------------------------------------------------------

- POAI shareholders to receive new Renovaro preferred stock in 1:1 exchange; preferred stock redeemable at $3.00 per share after 18 months.
- Deal conditions include minimum $15M fundraising by Renovaro and POAI shareholder approval; definitive agreement due by Feb 28, 2025.
- If POAI warrants not exercised by Jan 15, Renovaro will buy up to 2.33M POAI common shares at $1.07 each.
- Transaction provides access to POAI's biobank of 150,000 tumor specimens and AI platform with 92% drug-response accuracy.
- Combined entity aims to launch decision-support platform for oncologists in 2025, integrating multi-omic diagnostics and drug discovery.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527728/000173112225000037/0001731122-25-000037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527728/000173112225000037/e6266_8-k.htm
  HTML page:      https://secwatch.observer/filing/0001731122-25-000037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer